Abstract Age at onset in spinocerebellar ataxia type 3 (SCA3/MJD) is incompletely explained by the size of the CAG tract at the ATXN3 gene, implying the existence of genetic modifiers. A role of inflammation in SCA3 has been postulated, involving altered cytokines levels; promoter variants leading to alterations in cytokines expression could influence onset. Using blood from 86 SCA3 patients and 106 controls, this work aimed to analyse promoter variation of four cytokines (IL1A, IL1B, IL6 and TNF) and to investigate the association between variants detected and their transcript levels, evaluated by quantitative PCR. Moreover, the effect of APOE isoforms, known to modulate cytokines, was investigated. Correlations between cytokine variants and onset were tested; the cumulative modifier effects of cytokines and APOE were analysed. Patients carrying the IL6*C allele had a significant earlier onset (4 years in average) than patients carrying the G allele, in agreement with lower mRNA levels produced by IL6*C carriers. The presence of APOE*e2 allele seems to anticipate onset in average 10 years in patients carrying the IL6*C allele; a larger number of patients will be needed to confirm this result. These results highlight the pertinence of conducting further research on the role of cytokines as SCA3 modulators, pointing to the presence of shared mechanisms involving IL6 and APOE.
Introduction
Spinocerebellar ataxia type 3 (SCA3/MJD; MIM#109150; ORPHA98757) is the most common spinocerebellar ataxia worldwide. The number of coding CAG repeats at the causative locus, ATXN3, explains from 50 to 75 % of the age at onset variance (revised in Bettencourt and Lima 2011) , therefore implying the existence of additional familial factors, namely genetic. Several genetic modifiers have been proposed: the number of CAG repeats at several expansion loci (Jardim et al. 2003; Raposo et al. 2015a, b; Tezenas du Montcel et al. 2014) ; allelic variants at the apolipoprotein E (APOE) Peng et al. 2014 ) and glucosidase, beta, acid (GBA) genes (Siebert et al. 2012) ; and variation in the 3 0 UTR at the ATXN3 gene (Long et al. 2015) as well as the size of the normal SCA3 allele (França et al. 2012 ). In the ATXN3 gene, a repeat expansion above 50 triplets encodes an abnormally long polyglutamine (polyQ) stretch in the ataxin-3 protein (Maciel et al. 2001) ; mutant ataxin-3 is prone to misfolding and aggregation, triggering a cascade of pathological events (Evers et al. 2014) . The putative role of inflammation, namely the behaviour of interleukin 1 alpha (IL1A), interleukin 1 beta (IL1B), interleukin 6 (IL6) and tumour necrosis factor (TNF), has been investigated in polyQ diseases (Olejniczak et al. 2015) . In SCA3 brain tissue, IL1B and IL6 staining was found to be enhanced, as compared to controls; activated microglia and reactive astrocytes have also been observed (Evert et al. 2001 (Evert et al. , 2003 (Evert et al. , 2006 . Recently, eotaxin was found to be higher in serum of SCA3 asymptomatic carriers and in patients (da Silva Carvalho et al. 2015) . [ A localized at the promoter of respective cytokine genes have been related in vitro, ex and in vivo studies with differences in mRNA and/or protein levels of these cytokines (Dominici et al. 2002; Fishman et al. 1998; Hall et al. 2004; Wilson et al. 1997) . Moreover, a link between APOE and cytokines has been investigated, since APOE modulates inflammatory and immune responses in an isoform-dependent manner (Zhang et al. 2011) . We have previously shown that the APOE*e2 allele was significantly associated with an earlier age at onset in a cohort of SCA3 Azorean patients .
Given a possible role of inflammation in SCA3, we hypothesised that promoter variants leading to alterations of expression levels of cytokines could influence disease manifestation, namely onset. Using peripheral blood from a homogenous Azorean cohort of SCA3 patients, the present work aimed to analyse variants in the promoter regions of four main cytokines: (rs1800629) , and to investigate the association between these variants and the respective transcript levels. Genotype-phenotype correlations were made to test the loci previously reported as potential modifiers of SCA3 onset. Moreover, the cumulative modifier effects of cytokines loci and APOE were also tested.
Subjects and Methods

Subjects
Eighty-six Azorean SCA3 patients, confirmed as carriers of the ATXN3 mutation and 106 apparently healthy controls, were included in this study. Controls were selected taking into account the ancestry, age and gender distribution of cases. The size of the (CAG)n tract was determined as previously reported (Bettencourt et al. 2008 ). Age at onset, defined as the age of appearance of gait disturbance and/or diplopia reported by the patient and/or a close relative, was recorded during clinical assessments performed at the Department of Neurology (Hospital do Divino Espírito Santo-HDES, Ponta Delgada). APOE genotypes from SCA3 patients were considered for statistical analysis; genotyping was performed as in Bettencourt and colleagues . All samples were collected after informed consent. This study is a part of a project approved by the Ethics Committee of HDES.
DNA Isolation and Multiplex PCR-RFLP
DNA was extracted from all samples using standard procedures. A multiplex polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) was developed to analyse variants in the promoter of four cytokines:
The set of primers (0.2 lM of each one per reaction) for each cytokine variant as well as multiplex PCR-RFLP reactions mixture and conditions is described in supplementary Table 1 .
RNA Isolation and qPCR
A subset of 54 SCA3 patients was selected to measure cytokines mRNA levels. Signs of inflammatory or infective conditions were annotated by accessing the clinical records of patients; patients presented any of the above-mentioned conditions were not included. mRNA cytokine levels were also determined in 33 controls. Four pre-validated TaqMan Gene Expression Assays (Hs00174092_m1, Hs01555410_m1, Hs00985639_m1 and Hs99999043_m1 from Applied Biosystems) were used to measure cytokines mRNA levels. RNA isolation and quantification, cDNA synthesis, quantitative PCR (qPCR) conditions, as well as calculation of relative expression values have been performed as described elsewhere (Raposo et al. 2015a ).
Statistical Analysis
Allele and genotype frequencies were estimated for all analysed loci, and Hardy-Weinberg equilibrium (HWE) was tested. Allelic/genotypic frequencies for controls (N = 106) were compared with available data for other European and non-European populations. An ANCOVA, using age at sampling as covariate, was run to compare transcript levels between cytokine genotypes. The effects of the CAG length in expanded allele on age at onset, as well as the presence/absence of each cytokine allelic variant were assessed using a linear fitting model. Equality of variances between groups was verified by the Levene's test. An ANCOVA, using the CAG length in expanded allele as covariate, was conducted to compare estimated age at onset between: (1) cytokine genotypes; or (2) cytokine alleles; or (3) interaction of APOE*e2 allele and cytokine genotypes; or (4) interaction of APOE*e2 allele and allelic variants. For two or more pairwise comparisons (comparisons between cytokine genotypes), p values were adjusted using the Bonferroni procedure. Significant effects resulting from the ANCOVA comparisons, obtained only for IL6 allelic variants, were further tested. These correlations were confirmed: (a) using a generalized estimating equation test, where kinship was used as repetitive measure within subjects and (b) using the subset of 38 unrelated SCA3 patients (patients who shared grandparents were considered related). All statistical analyses were performed in IBM SPSS Statistics 22 (IBM Corp. Released 2013). A statistically significant result lower than 0.05 was considered for all tests performed.
Results
Gender and age at collection for the studied subjects are shown in Fig. 1 . Genotypes for the ATXN3 locus (N = 86) in patients, as well as relevant clinical data are displayed in Fig. 1 .
Loci were in conformity with Hardy-Weinberg equilibrium expectations, with the exception of IL1A and IL6 loci in SCA3 patients (supplementary Table 2 ). Pairwise differentiation exact test failed to detect significant differences in allelic or genotypic IL1A, IL1B and TNF frequencies between SCA3 patients and population-matched controls. At the IL6 locus, a statistically significant difference was obtained when comparing all patients with controls, which should reflect the excess of the C allele in the patients group; no differences, however, were detected when considering only unrelated patients (supplementary Table 2 ).
In SCA3 patients, no significant differences were obtained when comparing mRNA levels by genotypes (Fig. 2) . The effects of promoter allelic variants on mRNA levels were confirmed: the IL1A*T allele, the IL1B*T allele, the IL6*G allele and the TNF*A allele were associated with higher mRNA levels (Fig. 2 ), in accordance with previous studies. The mRNA levels by cytokine genotype varied similarly in controls (data not shown).
A negative correlation between the size of ATXN3 expanded allele of SCA3 patients and age at onset was observed (N = 86, r = -0.804, p \ 0.0005). The explanation of the age at onset variance provided by the CAG length in expanded allele was 65 % (F = 154.1, p \ 0.0005). An improvement of the previously model was observed only when the presence/absence of the IL6*C variant was added, which significantly contributed to the variance of the age at onset, by additionally explaining 1.9 % (N = 86, part correlation coefficient = 0.138, p \ 0.05).
Patients carrying the IL1A*T allele or the IL1B*T allele or the IL6*C allele all showed a tendency for an earlier age at onset (adjusted for mean CAG length) compared to patients homozygous for IL1A*C allele or the IL1B*C allele or the IL6*G allele (supplementary Table 3 ). Age at onset was anticipated by 4 years in average in patients carrying the IL6*C (N = 66, F(1,83) = 4.7, p = 0.03). The use of a generalized estimating equation test accounting for relatedness and the earlier onset in patients carrying the IL6*C allele confirmed that this result was not due to patients relatedness (Wald V 2 = 3.8, p = 0.05); the same tendency was observed when analysing only unrelated patients (N = 38). In the present cohort (N = 86), the presence of the APOE*e2 allele explained 3.4 % (p = 0.003) of variance in age at onset. The presence of APOE*e2 allele significantly anticipated onset in average 10 years in patients carrying one or two copies of the IL6*C allele (p = 0.005, Fig. 3) . Fitting a linear model, estimated age at onset (F(3,81) = 63.001, p \ 0.0005) using the APOE and IL6 loci alongside with the CAG size in expanded allele could be calculated by applying the formula: age at onset = 230.117-2.686 9 (CAG n in expanded allele)-3.272 9 (presence/absence of IL6*C allele)-6.911 9 (presence/absence of APOE*e2 allele).
Discussion
A significant association between IL6 c.-174G [ C variation and age at onset was, nevertheless, identified; patients carrying the IL6*C allele presented, in average, an onset 4 years earlier than the one displayed by patients homozygous for the G allele. We further observed a tendency for lower mRNA levels in patients carrying the IL6*C allele compared to GG homozygous, a result which is in agreement with previous findings (Fishman et al. 1998 ). Fishman and colleagues had suggested that IL6 c.-174G [ C variation is near to a glucocorticoid receptor (GR)-binding site as well as G [ C position could potentiate the creation for a binding site for the transcription factor nuclear factor 1 (NF1), implying, in both cases, the repression of transcription (Fishman et al. 1998 ). In our cohort, the low mRNA levels of IL6 produced by the IL6*C carriers were associated with a premature SCA3 onset, suggesting that in SCA3 patients' cells, such low levels could negatively contribute to cellular dysfunction, leading to the premature appearance of the first symptoms. Nishimura and colleagues (Nishimura et al. 2001) previously reported an association between IL1B*C allele and SCA6 onset; however, this association was not confirmed in our cohort of patients. In this study, an anticipation of onset (average of 10 years) was observed in patients carrying the APOE*e2 allele and one or two copies of the IL6*C allele. Although there are no published data for IL6, APOE is known to suppress the secretion of TNF and IL1B, the APOE*e2 isoform being associated with the lowest levels of secretion (Zhang et al. 2011) .
Even considering the homogeneity features of our patient's cohort, since sample size in this study is limited, the genotype-phenotype associations described should be ) by genotypes in 54 SCA3 patients. Expression values were adjusted for age at blood collection (50 years). In the comparisons performed by IL1A or IL6 genotype, Bonferroni adjusted p values were obtained by an ANCOVA procedure. IL1B and TNF mRNA levels were not successfully quantified for one patient Fig. 3 Estimated age at onset was calculated taking in consideration the cumulative effect of APOE*e2 allele and IL6 variation.
=1
The difference was in average of 4 years (ANCOVA, p = 0.03).
=2
The difference was in average of 10 years (t test, p = 0.005). T test was calculated using the OpenEpi, version 3.03 (Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health. www.OpenEpi.com, updated in 2014/09/22). APOE genotype was not successfully obtained in one patient replicated in a larger Azorean sample, when available, as well as in independent cohorts. Globally, results highlight the pertinence of further research on the role of cytokines as modulators of SCA3 onset, pointing to the presence of shared mechanisms involving IL6 and APOE.
